Adding Palbociclib to Maintenance Anti-HER2 and Endocrine Therapies Improves PFS Over Standard Therapy in Patients with HR-positive, HER2-positive MBC By Ogkologos - February 5, 2026 313 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PATINA study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Capmatinib Shows Activity in Advanced NSCLC with a MET Exon 14... September 8, 2020 New Survey Highlights the Role of Clinical Practice Guidelines to Improve... March 12, 2026 FDA Approves Atezolizumab as Adjuvant Treatment for Non-Small Cell Lung Cancer October 22, 2021 Begin Each Day… January 20, 2021 Load more HOT NEWS Embracing Bravery When You Have a Genetic Cancer Disease Study Advances Fertility Preservation Approach for Male Cancer Survivors How to Spot Suspicious Herb and Supplement Claims During Cancer Assessment of Patients’ Perspective on the Consequences of the COVID-19 Pandemic...
